Verona Pharma plc Pdmr Dealing

 
TIDMVRP 
 
   LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that, on March 8, 2019, Dr. David 
Ebsworth, Chairman of the Company, purchased a further 17,500 ordinary 
shares of 5 pence each in the Company (the "Ordinary Shares") at a price 
of 57 pence per Ordinary Share and a total purchase price of 
GBP9,975.00. Following the acquisition, Dr. Ebsworth will have an 
interest in the Company of 235,387 Ordinary Shares, representing 0.22% 
of the Company's issued share capital. 
 
   The notification set out below is provided in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
 
 
 
1   Details of the person discharging managerial responsibilities/person 
     closely associated 
    ---------------------------------------------------------------------------------------------- 
a)  Name                                                         David Ebsworth 
    -----------------------------------------------------------  --------------------------------- 
2   Reason for the notification 
    ---------------------------------------------------------------------------------------------- 
a)  Position/status                                              Chairman 
    -----------------------------------------------------------  --------------------------------- 
b)  Initial notification/Amendment                               Initial notification 
    -----------------------------------------------------------  --------------------------------- 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ---------------------------------------------------------------------------------------------- 
a)  Name                                                         Verona Pharma plc 
    -----------------------------------------------------------  --------------------------------- 
b)  LEI                                                          213800EVI6O6J3TIAL06 
    -----------------------------------------------------------  --------------------------------- 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    ---------------------------------------------------------------------------------------------- 
a)  Description of the financial instrument, type of instrument  Ordinary Shares of 5 pence each 
     Identification code                                          GB00BYW2KH80 
    -----------------------------------------------------------  --------------------------------- 
b)  Nature of the transaction                                    David Ebsworth purchased 17,500 
                                                                 Ordinary Shares 
    -----------------------------------------------------------  --------------------------------- 
c)  Price(s) and volume(s)                                       Price(s)   Volume(s) 
                                                                 ---------  ---------------------- 
                                                                 57 pence   17,500 Ordinary Shares 
                                                                 per 
                                                                 Ordinary 
                                                                 Share 
    -----------------------------------------------------------  ---------  ---------------------- 
d)  Aggregated information                                       N/A 
     --    Aggregated volume 
 
     --    Price 
    -----------------------------------------------------------  --------------------------------- 
e)  Date of the transaction                                      8 March 2019 
    -----------------------------------------------------------  --------------------------------- 
f)  Place of the transaction                                     London Stock Exchange, AIM 
    -----------------------------------------------------------  --------------------------------- 
 
 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
 Victoria Stewart, Director of Communications 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 7710 7600 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison
(END) Dow Jones Newswires
March 11, 2019 05:48 ET (09:48 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Oct 2024 to Nov 2024